The reduction in FMRP likely contributes to the symptoms seen in FXS patients, specifically because FMRP is an RNA-binding protein that acts as a translational regulator of neuronal mRNAs of many messages that affect synaptic plasticity, connectivity, and memory in the central nervous system [48]. This evidence concerns the gene FMR1 and fragile X syndrome.